Semiconductor startup Sophrosyne Technologies, based in Bengaluru, has secured $2 million in seed funding, marking a significant step toward expanding its biosensing SoC chip technology for wearable and digital-health devices.
The funding round was led by Bluehill.VC, a Chennai-based deep-tech venture capital firm, and follows Sophrosyne’s recent receipt of a $1.2 million grant from MeitY’s DLI scheme after passing detailed technical diligence.
Sophrosyne Technologies is developing a unified, multi-vital biosensing system-on-chip (SoC) designed specifically for wearable devices and digital health applications.
The chip supports precise measurement of vital signals such as ECG, PPG, respiration, and temperature while maintaining ultra-low energy consumption and a compact silicon footprint. This integration empowers device makers to offer richer, continuous health monitoring in advanced consumer and medical wearables.
The proceeds from the investment will help Sophrosyne progress from prototype silicon to volume development, scale firmware engineering, and expand early deployments both in India and abroad. The company also plans to use the capital for global OEM engagement.
Bluehill.VC focuses exclusively on deep-tech investments in areas including semiconductors, energy, robotics, defence, and industrial IoT, supporting innovators from India aiming to achieve global scale in their respective domains.
Leadership Comments
Manish Srivastava, co-founder and CEO of Sophrosyne Technologies, commented, “Having a deep-tech investor like Bluehill.VC, supported by leaders such as Vinod Dham, Manu Iyer, and Sridhar Parthasarathi, provides us world-class semiconductor guidance and the discipline and clarity to scale this technology globally. This partnership sets us apart and accelerates our vision for next-generation digital health solutions.”
